

What is claimed is:

1. A liquid composition comprising an antibody against human interleukin-4 receptor alpha, wherein the liquid composition comprises the antibody at a concentration of 100-165 mg/ml; and a buffer, a protective agent and a surfactant which serve as excipients, and wherein the antibody comprises a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 4, a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 8, a light chain constant region comprising the amino acid sequence as set forth in SEQ ID NO: 9 and a heavy chain constant region comprising the amino acid sequence as set forth in SEQ ID NO: 10; and the liquid composition has a pH of 6.2 ± 0.2 ; and wherein the buffer is histidine hydrochloride buffer at a concentration of 5-10 mmol/L, the protective agent is a combination of 60-150 mmol/L trehalose and 80-120 mmol/L sodium chloride, and the surfactant is 0.01%-0.2% Tween 80.
2. The liquid composition according to Claim 1, wherein in the liquid composition, the antibody is present at a concentration of 130-165 mg/ml.
3. The liquid composition according to Claim 1, wherein in the liquid composition, the antibody is present at a concentration of 150 ± 5 mg/ml.
4. The liquid composition according to Claim 1, wherein the buffer is histidine hydrochloride buffer at a concentration of 10 mmol/L.
5. The liquid composition according to Claim 1, wherein in the liquid composition, the protective agent is a combination of 60 mmol/L trehalose and 100 mmol/L sodium chloride.
6. The liquid composition according to Claim 1, wherein the surfactant is 0.01-0.03% Tween 80.

7. The liquid composition according to Claim 1, wherein the surfactant is 0.02% Tween 80.
8. The liquid composition according to any one of Claims 1 to 7, wherein the liquid composition is a formulation for injection.
9. The liquid composition according to any one of Claims 1 to 7, wherein the liquid composition is a formulation for subcutaneous or intravenous injection.
10. The liquid composition according to any one of Claims 1 to 7, wherein the liquid composition comprises:
130-165 mg/ml of the antibody;
10 mmol/L histidine hydrochloride;
60 mmol/L trehalose;
100 mmol/L sodium chloride;
0.02% Tween 80; and
the liquid composition has a pH of 6.2 ± 0.2 .
11. The liquid composition according to Claim 10, wherein in the liquid composition, the antibody is present at a concentration of 150 ± 5 mg/ml.
12. The liquid composition according to Claim 11, wherein the liquid composition has a pH of 6.2 ± 0.05 .
13. Use of the liquid composition according to any one of Claims 1 to 12 for manufacturing a medicament for the treatment of inflammation or allergic disease.
14. The use according to Claim 13, wherein the inflammation or allergic disease includes autoimmune disease.

15. The use according to Claim 13, wherein the inflammation or allergic disease is allergic dermatitis, asthma, eosinophilic esophagitis, eczema, allergic rhinitis, nasal polyp, or rheumatoid arthritis.

16. A container, wherein the container comprises the liquid composition according to any one of Claims 1 to 15.

17. A kit comprising the container according to Claim 16.